Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Overview of attention for article published in Lancet Oncology, December 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news: 6 news outlets
policy: 2 policy sources
twitter: 58 X users

patent: 16 patents
guideline: 4 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 396 Mendeley

So far, Altmetric has seen 9 news stories from 6 outlets.

CAR T-Cell Therapy for Relapsed/Refractory Follicular Lymphoma

MedPage Today, 14 May 2025

Spotlight On > Follicular Lymphoma Updated trial results confirm long-term benefit with the three approved therapies by Mike…

Are We on the Brink of Redefining Follicular Lymphoma?

Medscape, 12 May 2025

We’ve long known follicular lymphoma (FL) as a slow-growing, incurable disease that tends to relapse.

Episode 4: CAR T-Cell Therapy for B-Cell Lymphomas

Medscape, 11 Jul 2023

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple…

Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell Lymphoma

OncLive, 28 Jun 2023

Akash Mukherjee, MD Chimeric antigen receptor (CAR) T-cell therapy has proven to be an effective adoptive cellular therapy…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 5 additional news stories.